Achieve Life Sciences, Inc. (ACHV) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value (m); Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | (m) | Share-based compensation / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | (m) | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 9.91M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | (m) | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | (m) | $9.91M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | (m) | (m) | $5.84M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | (m) | (m) | $8.76M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $26.42M | (m) | $8.70M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $28.71M | (m) | $7.70M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $27.11M | (m) | $6.27M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $22.82M | (m) | $5.33M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $17.64M | (m) | $4.07M | (m) | $2.77M | (m) | (m) | (m) | Reported |
| 2024-06-30 | $13.61M | (m) | $3.91M | (m) | $3.19M | (m) | (m) | (m) | Reported |
| 2024-03-31 | $13.08M | (m) | $3.64M | (m) | $3.09M | (m) | (m) | (m) | Reported |
| 2023-12-31 | $15.81M | (m) | $3.44M | (m) | $2.85M | (m) | (m) | (m) | Reported |
| 2023-09-30 | $22.31M | (m) | $4.23M | (m) | $2.61M | (m) | (m) | (m) | Reported |
| 2023-06-30 | $28.60M | (m) | $3.88M | (m) | $2.31M | (m) | (m) | (m) | Reported |
| 2023-03-31 | $31.22M | (m) | $3.53M | (m) | $2.00M | (m) | (m) | (m) | Reported |
| 2022-12-31 | $30.08M | (m) | $3.27M | (m) | $1.79M | (m) | (m) | (m) | Reported |
| 2022-09-30 | $25.97M | (m) | $2.99M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $20.69M | (m) | $2.69M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $22.71M | (m) | $2.47M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $23.97M | (m) | $2.19M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | $21.81M | (m) | $2.09M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | $19.11M | (m) | $1.84M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $10.98M | (m) | $1.53M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $6.88M | (m) | $1.29M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | $6.30M | (m) | $1.18M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | $6.23M | (m) | $1.20M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | $7.16M | (m) | $1.21M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $9.67M | $0.00 | $1.20M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | $9.99M | (m) | $1.18M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | $9.71M | (m) | $1.08M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | $8.72M | (m) | $963.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-12-31 | $5.87M | $0.00 | $854.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $5.94M | (m) | $784.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-06-30 | $5.22M | (m) | $303.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-03-31 | $4.24M | (m) | $318.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-12-31 | $3.10M | (m) | $348.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $15.53M | (m) | $548.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | $7.17M | (m) | $685.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | $11.06M | (m) | $1.39M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | $14.79M | (m) | $1.65M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $19.67M | (m) | $1.64M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $24.20M | (m) | $2.49M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $26.08M | (m) | $2.28M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $25.11M | (m) | $2.33M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-09-30 | $28.37M | (m) | $2.83M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-06-30 | $29.66M | (m) | $3.07M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-03-31 | $32.99M | (m) | $3.38M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | $46.22M | (m) | $3.86M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-09-30 | $49.57M | (m) | $3.31M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $57.98M | (m) | $3.25M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | $61.37M | (m) | $3.09M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $55.32M | (m) | $2.83M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-09-30 | $57.77M | (m) | $3.06M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-06-30 | $52.66M | (m) | $2.75M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-03-31 | $45.72M | (m) | $2.60M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-12-31 | $39.95M | (m) | $2.17M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-09-30 | $31.78M | (m) | $1.93M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-06-30 | $22.70M | (m) | $1.66M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2012-03-31 | $21.78M | (m) | $1.24M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-12-31 | $21.55M | (m) | $1.19M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $18.48M | (m) | $642.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $20.21M | (m) | $380.00K | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Insight Molecular Diagnostics Inc. (IMDX) | United States | $0.129B | -3.90 |
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |